In view of the current potential obstacles in reaching SCs for targeted gene therapy, and the fact that the majority of CMT subtypes are due to mutations in myelin genes, we believe that NT-3 gene therapy is well positioned with potential for providing efficacy in this group of CMT patients. Here, NTF3 is linked to Charcot-Marie-Tooth disease.